drugset / Trial / NCT02614937
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Phase 1/2
Completed
20 enrolled
Ohr Pharmaceutical Inc.
Cumberland Valley Retina Consultants, PC · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This was a prospective, single center, open label, randomized study evaluating the biological effect of squalamine lactate ophthalmic solution, 0.2% combined with intravitreous ranibizumab in patients with macular edema secondary to branch, hemi-central and central retinal vein occlusion (BRVO, HRVO, CRVO).
Timeline
- Start
- 2013-04
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Squalamine | Unknown | 0.2 % | Topical |
| Background | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |